PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29316176-8 2018 The prandial insulin glulisine dosage for arm A and arm B was 9.3 and 10.1 units, respectively (P = .39). glulisine 21-30 insulin Homo sapiens 13-20 29462782-3 2018 This study describes a qualitative method for detection of insulin analogues (lispro, aspart, glulisine, glargine, degludec, detemir) in human urine. glulisine 94-103 insulin Homo sapiens 59-66 29316176-1 2018 AIMS: To evaluate the glycaemic control achieved by prandial once-daily insulin glulisine injection timing adjustment, based on a continuous glucose monitoring sensor, in comparison to once-daily insulin glulisine injection before breakfast in patients with type 2 diabetes who are uncontrolled with once-daily basal insulin glargine. glulisine 80-89 insulin Homo sapiens 72-79 26838553-0 2016 A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine. glulisine 120-129 insulin Homo sapiens 56-63 28762200-1 2017 PURPOSE: Comparison of the dissociation kinetics of rapid-acting insulins lispro, aspart, glulisine and human insulin under physiologically relevant conditions. glulisine 90-99 insulin Homo sapiens 65-72 30603298-3 2016 Her plasma insulin concentration was unexpectedly low during use of insulin lispro, but it was recovered by changing from the zinc-containing insulin lispro to the zinc-free insulin glulisine. glulisine 182-191 insulin Homo sapiens 11-18 27145344-11 2016 Insulin glulisine and degludec have not been studied in pregnancy. glulisine 8-17 insulin Homo sapiens 0-7 27168767-8 2016 Among the insulin analogues, which were not available in the SNTP Program, insulin glulisine showed the greatest increase in units dispensed (34.2 %). glulisine 83-92 insulin Homo sapiens 10-17 27168767-8 2016 Among the insulin analogues, which were not available in the SNTP Program, insulin glulisine showed the greatest increase in units dispensed (34.2 %). glulisine 83-92 insulin Homo sapiens 75-82 30603298-5 2016 A skin biopsy at the injection site of insulin lispro showed invasion of lymphocytes, neutrophils, and eosinophils, but a skin biopsy at the injection site of insulin glulisine showed invasion of only lymphocytes. glulisine 167-176 insulin Homo sapiens 159-166 25865292-2 2016 For continuous subcutaneous insulin infusion, the insulins of choice are the rapid-acting insulin analogues, insulin aspart, insulin lispro and insulin glulisine. glulisine 152-161 insulin Homo sapiens 50-57 27026836-6 2016 The patient"s glycemic control was continued with the administration of insulin glargine (30 units every 24 hours) and prandial insulin glulisine (five to eight units per meal). glulisine 136-145 insulin Homo sapiens 128-135 25865292-2 2016 For continuous subcutaneous insulin infusion, the insulins of choice are the rapid-acting insulin analogues, insulin aspart, insulin lispro and insulin glulisine. glulisine 152-161 insulin Homo sapiens 50-57 25865292-2 2016 For continuous subcutaneous insulin infusion, the insulins of choice are the rapid-acting insulin analogues, insulin aspart, insulin lispro and insulin glulisine. glulisine 152-161 insulin Homo sapiens 50-57 25865292-2 2016 For continuous subcutaneous insulin infusion, the insulins of choice are the rapid-acting insulin analogues, insulin aspart, insulin lispro and insulin glulisine. glulisine 152-161 insulin Homo sapiens 50-57 29159123-8 2016 Conclusions: Glargine/glulisine pharmacokinetics in type 1 diabetes can closely approximate physiologic insulin responses in healthy individuals during a day in which three standardized meals are consumed. glulisine 22-31 insulin Homo sapiens 104-111 29159123-9 2016 Additionally, when glulisine is dosed only five minutes pre-meal, systemic insulin concentration rises as rapidly as prandial endogenous insulin levels. glulisine 19-28 insulin Homo sapiens 75-82 29159123-9 2016 Additionally, when glulisine is dosed only five minutes pre-meal, systemic insulin concentration rises as rapidly as prandial endogenous insulin levels. glulisine 19-28 insulin Homo sapiens 137-144 25788506-10 2015 There is also a low quality of evidence to suggest that a fixed-dose analog regimen of insulin glargine with or without insulin glulisine is more effective than regular SSI for reducing blood glucose concentrations and postoperative complications. glulisine 128-137 insulin Homo sapiens 120-127 26568812-4 2015 The rapid-acting insulin analogues (insulin aspart, insulin lispro and insulin glulisine) all have similar pharmacokinetic and pharmacodynamic characteristics and clinical efficacy/safety profiles. glulisine 79-88 insulin Homo sapiens 17-24 26121460-6 2015 The mean insulin dose in the glargine/glulisine group was 0.76 +- 0.3 units/kg/day (glargine, 22 +- 9 units/day; glulisine, 31 +- 12 units/day) and was not different compared with NPH/regular group (0.75 +- 0.3 units/kg/day [NPH, 28 +- 12 units/day; regular, 23 +- 9 units/day]). glulisine 38-47 insulin Homo sapiens 9-16 25282010-7 2014 Insulin lispro, insulin aspart, and insulin glulisine are rapidly absorbed after injection and thus provide better coverage of the post-prandial glucose surge compared with human insulin. glulisine 44-53 insulin Homo sapiens 36-43 25621137-0 2015 Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes. glulisine 44-53 insulin Homo sapiens 36-43 25621137-1 2015 We investigated the efficacy and safety of switching to insulin glulisine (GLU) from other rapid-acting insulin analogs (Ra) in children with type 1 diabetes treated with multiple daily injections of insulin or continuous subcutaneous insulin infusion. glulisine 64-73 insulin Homo sapiens 56-63 25238698-6 2015 RESULTS: AUC-B 0-4 and AUC-D 0-6 were significantly lower with insulin glulisine than with regular insulin (AUC-B 0-4: 3.3 +- 4.7 vs. 6.2 +- 5.4 x 10(2) mmol/L minute, respectively, P = .028; AUC-D 0-6: 1.8 +- 7.3 vs. 6.5 +- 6.2 x 10(2) mmol/L minute, respectively, P = .023). glulisine 71-80 insulin Homo sapiens 63-70 25238698-7 2015 In contrast, AUC-L 0-6 was higher with insulin glulisine than with regular insulin (AUC-L 0-6: 7.6 +- 6.4 vs. 4.2 +- 8.7 x 10(2) mmol/L minute, respectively, P = .099), suggesting a prolonged hypoglycemic action of regular insulin after lunch. glulisine 47-56 insulin Homo sapiens 39-46 25238698-8 2015 CONCLUSIONS: Insulin glulisine effectively suppressed postprandial hyperglycemia, whereas regular insulin caused a prolonged hypoglycemic action. glulisine 21-30 insulin Homo sapiens 13-20 25238698-9 2015 These findings support the effectiveness and safety of insulin glulisine in patients with type 2 diabetes and severe renal insufficiency. glulisine 63-72 insulin Homo sapiens 55-62 25739586-1 2015 The analogue insulin glulisine (Glu) shows both more rapid onset and shorter duration of action compared with the other rapid-acting insulin analogues. glulisine 21-30 insulin Homo sapiens 13-20 25739586-1 2015 The analogue insulin glulisine (Glu) shows both more rapid onset and shorter duration of action compared with the other rapid-acting insulin analogues. glulisine 21-30 insulin Homo sapiens 133-140 24639403-6 2014 RESULTS: Although bolus and basal insulin doses were almost unchanged before and after replacement therapy, switching to glulisine insulin for 24 weeks significantly decreased level of HbA1c , advanced glycation end products (AGEs), soluble receptor for AGEs (sRAGE), monocyte chemoattractant protein-1 (MCP-1) and urinary albumin excretion. glulisine 121-130 insulin Homo sapiens 131-138 24639403-10 2014 Replacement of short-acting insulin by glulisine significantly increased Diabetes Treatment Satisfaction Questionnaire scores. glulisine 39-48 insulin Homo sapiens 28-35 24949654-0 2014 Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin. glulisine 38-47 insulin Homo sapiens 30-37 24949654-0 2014 Efficacy of adding once-daily insulin glulisine in Japanese type 2 diabetes patients treated with insulin glargine and sitagliptin. glulisine 38-47 insulin Homo sapiens 98-105 24949654-9 2014 CONCLUSIONS: Adding once-daily insulin glulisine was more effective in controlling the glycemic fluctuation in Japanese type 2 diabetes patients treated with insulin glargine together with sitagliptin. glulisine 39-48 insulin Homo sapiens 31-38 24909933-2 2014 Insulin glulisine was much more stable than the other analogs and showed minimal degradation even in the absence of phenolic preservatives. glulisine 8-17 insulin Homo sapiens 0-7 24949654-9 2014 CONCLUSIONS: Adding once-daily insulin glulisine was more effective in controlling the glycemic fluctuation in Japanese type 2 diabetes patients treated with insulin glargine together with sitagliptin. glulisine 39-48 insulin Homo sapiens 158-165 25054310-0 2014 Safety results from OCAPI: a European Observational Cohort Study of insulin glulisine-treated children aged 6-12 years with type 1 diabetes. glulisine 76-85 insulin Homo sapiens 68-75 25054310-1 2014 OBJECTIVE: Data on the safety of insulin glulisine for type 1 diabetes are limited in paediatric populations. glulisine 41-50 insulin Homo sapiens 33-40 25054310-8 2014 Only 1 participant (9-12 years age group) experienced a serious class-effect risk possibly related to insulin glulisine (severe hypoglycaemia requiring an Emergency Department visit). glulisine 110-119 insulin Homo sapiens 102-109 25054310-10 2014 CONCLUSIONS: Insulin glulisine has a good safety profile in children with type 1 diabetes aged 6-12 years, with generally low rates of severe hypoglycaemia and few adverse reactions. glulisine 21-30 insulin Homo sapiens 13-20 24909933-4 2014 When depleted of preservatives, insulin glulisine dissociates from higher molecular weight species into a number of intermediate molecular weight species, in between monomer and hexamer, whereas insulin aspart and insulin lispro dissociate into monomers and dimers. glulisine 40-49 insulin Homo sapiens 32-39 24909933-6 2014 Insulin glulisine"s dissociation to intermediate molecular weight species appears to help minimize its degradation during incubation at 37 C. glulisine 8-17 insulin Homo sapiens 0-7 24855159-3 2014 Specifically, there are a considerable number of reports demonstrating that prandial insulin analogs (lispro, aspart, glulisine) have pharmacokinetic and pharmacodynamic profiles closer to normal, with resulting faster onset and offset of insulin effect when compared with regular human insulin. glulisine 118-127 insulin Homo sapiens 85-92 24855159-3 2014 Specifically, there are a considerable number of reports demonstrating that prandial insulin analogs (lispro, aspart, glulisine) have pharmacokinetic and pharmacodynamic profiles closer to normal, with resulting faster onset and offset of insulin effect when compared with regular human insulin. glulisine 118-127 insulin Homo sapiens 239-246 24855159-3 2014 Specifically, there are a considerable number of reports demonstrating that prandial insulin analogs (lispro, aspart, glulisine) have pharmacokinetic and pharmacodynamic profiles closer to normal, with resulting faster onset and offset of insulin effect when compared with regular human insulin. glulisine 118-127 insulin Homo sapiens 239-246 24855160-3 2014 Specifically, there are a considerable number of reports demonstrating that prandial insulin analogs (lispro, aspart, glulisine) have pharmacokinetic and pharmacodynamic profiles closer to normal, with resulting faster onset and offset of insulin effect when compared with regular human insulin. glulisine 118-127 insulin Homo sapiens 85-92 24855160-3 2014 Specifically, there are a considerable number of reports demonstrating that prandial insulin analogs (lispro, aspart, glulisine) have pharmacokinetic and pharmacodynamic profiles closer to normal, with resulting faster onset and offset of insulin effect when compared with regular human insulin. glulisine 118-127 insulin Homo sapiens 239-246 24855160-3 2014 Specifically, there are a considerable number of reports demonstrating that prandial insulin analogs (lispro, aspart, glulisine) have pharmacokinetic and pharmacodynamic profiles closer to normal, with resulting faster onset and offset of insulin effect when compared with regular human insulin. glulisine 118-127 insulin Homo sapiens 239-246 22578200-0 2012 Micro- and macrovascular outcomes in Type 2 diabetic patients treated with insulin glulisine or human regular insulin: a retrospective database analysis. glulisine 83-92 insulin Homo sapiens 75-82 24033863-1 2014 AIMS: We aimed to identify predictors of hypoglycaemia in patients with poorly controlled type 2 diabetes treated with a single daily bolus of insulin glulisine on top of insulin glargine and oral antidiabetic drugs (basal-plus regimen). glulisine 151-160 insulin Homo sapiens 143-150 24351186-5 2013 Under these conditions, the overall stability of rapid-acting insulin analogs was similar for insulin lispro, insulin aspart, and insulin glulisine, although insulin glulisine showed greater susceptibility to insulin precipitation and catheter occlusions. glulisine 138-147 insulin Homo sapiens 62-69 23425652-2 2013 The objective of this study was to determine if insulin glulisine (Apidra), another rapid-acting insulin analog, would be superior in controlling postprandial hyperglycemia in children with T1DM. glulisine 56-65 insulin Homo sapiens 48-55 23425652-2 2013 The objective of this study was to determine if insulin glulisine (Apidra), another rapid-acting insulin analog, would be superior in controlling postprandial hyperglycemia in children with T1DM. glulisine 56-65 insulin Homo sapiens 97-104 23425652-7 2013 RESULTS: Mean baseline BG values for insulin glulisine (136.4 +- 15.7 mg/dL; mean +- SD) and aspart (133.4 +- 14.7 mg/dL) were similar (P = .34). glulisine 45-54 insulin Homo sapiens 37-44 30349602-1 2013 Introduction: The Glulisine in Combination with Insulin Glargine in an Intensified Insulin Regimen (GINGER) study compared insulin glargine plus insulin glulisine with premixed insulin in the treatment of patients with Type 2 diabetes mellitus (T2DM). glulisine 18-27 insulin Homo sapiens 83-90 30349602-6 2013 In patients with >=1 episode of hypoglycaemia during treatment, the overall hypoglycaemic event rate was significantly lower (-26.5 %) in patients receiving glargine plus glulisine versus overall premixed insulin (18.5+-26.3 versus 25.1+-41.1; p=0.044) and significantly lower (-40.7 %) than in patients receiving biphasic insulin aspart 70/30 (31.1+-52.7; p=0.009). glulisine 174-183 insulin Homo sapiens 208-215 30349602-6 2013 In patients with >=1 episode of hypoglycaemia during treatment, the overall hypoglycaemic event rate was significantly lower (-26.5 %) in patients receiving glargine plus glulisine versus overall premixed insulin (18.5+-26.3 versus 25.1+-41.1; p=0.044) and significantly lower (-40.7 %) than in patients receiving biphasic insulin aspart 70/30 (31.1+-52.7; p=0.009). glulisine 174-183 insulin Homo sapiens 326-333 30349602-8 2013 Conclusion: This post-hoc analysis of the GINGER study showed that the frequency of hypoglycaemia in T2DM patients was lowered to a greater extent by insulin glargine plus insulin glulisine in a comparison with premixed biphasic insulin aspart 70/30 than was previously shown in a comparison with overall premixed insulin. glulisine 180-189 insulin Homo sapiens 150-157 30349602-8 2013 Conclusion: This post-hoc analysis of the GINGER study showed that the frequency of hypoglycaemia in T2DM patients was lowered to a greater extent by insulin glargine plus insulin glulisine in a comparison with premixed biphasic insulin aspart 70/30 than was previously shown in a comparison with overall premixed insulin. glulisine 180-189 insulin Homo sapiens 172-179 24265369-0 2013 Insulin glulisine may cause a disease resembling insulin autoimmune syndrome: case report. glulisine 8-17 insulin Homo sapiens 0-7 23047542-1 2013 Insulin glulisine (Glu) is a rapidly-acting insulin analog with a faster onset of action than the other insulin analogs of its class, which are insulin aspart (Asp) and insulin lispro (Lisp). glulisine 8-17 insulin Homo sapiens 0-7 23047542-1 2013 Insulin glulisine (Glu) is a rapidly-acting insulin analog with a faster onset of action than the other insulin analogs of its class, which are insulin aspart (Asp) and insulin lispro (Lisp). glulisine 8-17 insulin Homo sapiens 44-51 22578200-1 2012 OBJECTIVE: Insulin glulisine has a higher efficacy in reducing postprandial glucose excursions and in restoring normal postprandial microcirculation than rapid human insulin. glulisine 19-28 insulin Homo sapiens 11-18 22578200-2 2012 The aim was to compare the incidence of macro- and microvascular outcomes in Type 2 diabetic patients treated with insulin glulisine or regular human insulin. glulisine 123-132 insulin Homo sapiens 115-122 22578200-6 2012 RESULTS: Overall, risk for macro- or microvascular outcomes was 20% lower for insulin glulisine users (p < 0.05). glulisine 86-95 insulin Homo sapiens 78-85 22578200-8 2012 Also for microvascular complications, the adjusted hazard ratios for retinopathy, nephropathy and neuropathy were below 1.0, indicating a lower risk for the insulin glulisine group, however, which was significant for neuropathy only (HR: 0.74; 0.58 - 0.93). glulisine 165-174 insulin Homo sapiens 157-164 22578200-9 2012 CONCLUSIONS: Prescription of the rapid-acting insulin analog glulisine was associated with a reduced incidence of macro- and microvascular outcomes in Type 2 diabetes under real-life conditions. glulisine 61-70 insulin Homo sapiens 46-53 22699288-10 2012 CONCLUSIONS: Reduction of initial glargine/glulisine insulin weight-based dosing in hospitalized patients with diabetes and renal insufficiency reduced the frequency of hypoglycemia by 50% without compromising the control of hyperglycemia. glulisine 43-52 insulin Homo sapiens 53-60 22321739-5 2012 Some studies have suggested that insulin glulisine has a slightly faster onset of action compared with insulin lispro or insulin aspart, but this has not been translated into demonstrable clinical benefit. glulisine 41-50 insulin Homo sapiens 33-40 20963448-4 2012 Prick tests revealed an allergy specifically to zinc, and the patient was treated with zinc-free glulisine insulin. glulisine 97-106 insulin Homo sapiens 107-114 22538135-3 2012 This article investigates and compares the intrinsic fibrillation of three fast-acting insulin analogs--lispro, aspart, and glulisine--as a function of their primary protein structure and exclusive of the stabilizing excipients that are added to their respective commercial formulations. glulisine 124-133 insulin Homo sapiens 87-94 22649410-5 2012 The rapid-acting insulin analogs, lispro, aspart, and glulisine, have a rapid onset and shorter duration of action. glulisine 54-63 insulin Homo sapiens 17-24 21679291-0 2011 Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month "proof-of-concept" study. glulisine 77-86 insulin Homo sapiens 69-76 21812890-8 2011 RESULTS: At study end, insulin glulisine achieved similar glycaemic control whether it was administered before or after meals (HbA(1c) : 7.04% premeal vs. 7.16% postmeal, p = NS). glulisine 31-40 insulin Homo sapiens 23-30 21724289-0 2011 Insulin glulisine may ameliorate nocturnal hypoglycemia related to insulin antibody--a case report. glulisine 8-17 insulin Homo sapiens 0-7 21724289-0 2011 Insulin glulisine may ameliorate nocturnal hypoglycemia related to insulin antibody--a case report. glulisine 8-17 insulin Homo sapiens 67-74 22013886-0 2012 Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. glulisine 151-160 insulin Homo sapiens 143-150 22013886-1 2012 BACKGROUND: We compared telecare and conventional self-monitored blood glucose (SMBG) programs for titrating the addition of one bolus injection of insulin glulisine in patients with type 2 diabetes uncontrolled on oral hypoglycemic agents for >=3 months who were first titrated with basal insulin glargine. glulisine 156-165 insulin Homo sapiens 148-155 21679291-2 2011 The efficacy of initiating and titrating a single bolus dose of insulin glulisine to baseline insulin glargine plus oral hypoglycaemic agents (OHAs) was investigated. glulisine 72-81 insulin Homo sapiens 64-71 21679291-10 2011 CONCLUSIONS: In people with T2DM inadequately controlled on basal insulin plus OHAs, adding a single injection of insulin glulisine prior to the main meal significantly improves glucose control without undesired side effects. glulisine 122-131 insulin Homo sapiens 66-73 21457066-0 2011 Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. glulisine 8-17 insulin Homo sapiens 0-7 22027323-7 2011 During the study, SoloSTAR was used to administer insulin glargine and/or insulin glulisine by 97.3% and 36.0% of patients, respectively (both: 27.0%). glulisine 82-91 insulin Homo sapiens 74-81 21732826-1 2011 : "Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial". glulisine 11-20 insulin Homo sapiens 3-10 21205115-0 2011 Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. glulisine 88-97 insulin Homo sapiens 80-87 21617101-0 2011 Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: successful treatment with the newest insulin analog glulisine. glulisine 136-145 insulin Homo sapiens 31-38 21617101-0 2011 Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: successful treatment with the newest insulin analog glulisine. glulisine 136-145 insulin Homo sapiens 66-73 21617101-0 2011 Diabetic ketosis caused by the insulin analog aspart-induced anti-insulin antibody: successful treatment with the newest insulin analog glulisine. glulisine 136-145 insulin Homo sapiens 66-73 21324825-6 2011 During the randomization phase, A1C reductions with insulin glulisine once or twice daily were noninferior to insulin glulisine 3 times daily (confidence intervals: -0.39 to 0.36 and -0.30 to 0.43; P>.5 for both). glulisine 60-69 insulin Homo sapiens 52-59 21134878-1 2011 OBJECTIVE: To compare how the rapid-acting insulin analogues (RAIAs) aspart, lispro, and glulisine perform in continuous subcutaneous insulin infusion (CSII) therapy regarding (1) pharmacokinetic properties, (2) chemical and physical stability, and (3) pump compatibility. glulisine 89-98 insulin Homo sapiens 134-141 21205115-5 2011 RESULTS: The area under the absolute glucose concentration-time curve between 0 and 1 h after insulin injection and maximal glucose concentration was significantly lower with glulisine than with aspart (p = 0.0455 and 0.0337, respectively). glulisine 175-184 insulin Homo sapiens 94-101 21205115-7 2011 Peak insulin concentration was significantly higher for glulisine than for insulin aspart (p < 0.0001). glulisine 56-65 insulin Homo sapiens 5-12 20805258-1 2010 OBJECTIVE: To compare the efficacy and safety of the rapid-acting insulin analog glulisine and regular insulin in hyperglycemic hospitalized patients. glulisine 81-90 insulin Homo sapiens 66-73 22267935-2 2011 Modifications of the insulin molecule have resulted in two long-acting insulin analogs (glargine and detemir) and three rapid-acting insulins (aspart, lispro, and glulisine) with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles. glulisine 163-172 insulin Homo sapiens 21-28 21437110-1 2010 Glulisine (Apidra( )) is a rapid-acting human insulin analog approved for use in children with diabetes mellitus >=4 years of age. glulisine 0-9 insulin Homo sapiens 46-53 21437110-4 2010 This review appraises the current available studies and reviews on insulin glulisine in children. glulisine 75-84 insulin Homo sapiens 67-74 20920444-2 2010 ClikSTAR (sanofi-aventis) is a novel reusable insulin pen for injecting either long-acting insulin glargine or short-acting insulin glulisine. glulisine 133-142 insulin Homo sapiens 47-54 20960101-3 2010 Glulisine is a new rapid-acting insulin analog for mealtime insulin supplementation. glulisine 0-9 insulin Homo sapiens 32-39 20960101-3 2010 Glulisine is a new rapid-acting insulin analog for mealtime insulin supplementation. glulisine 0-9 insulin Homo sapiens 60-67 20960101-4 2010 We compared the pharmacokinetics and pharmacodynamics end points between the two rapid-acting insulin analogs Glulisine and Lispro. glulisine 110-119 insulin Homo sapiens 94-101 20960101-14 2010 Insulin analogs Glulisine and Lispro were proved to have equivalent pharmacokinetic and pharmacodynamic parameters when administered to healthy Chinese adults, but with Glulisine showing greater AUC(0-1h) after injection. glulisine 16-25 insulin Homo sapiens 0-7 20960101-14 2010 Insulin analogs Glulisine and Lispro were proved to have equivalent pharmacokinetic and pharmacodynamic parameters when administered to healthy Chinese adults, but with Glulisine showing greater AUC(0-1h) after injection. glulisine 169-178 insulin Homo sapiens 0-7 20078323-14 2010 Long-acting basal insulin analogs (glargine, detemir) are suitable and preferred for the basal component of therapy; rapid-acting insulin analogs (aspart, lispro, glulisine) are recommended for bolus and correction doses. glulisine 163-172 insulin Homo sapiens 130-137 19366972-8 2009 CONCLUSIONS: Regular and glulisine insulin are equally effective during the acute treatment of DKA. glulisine 25-34 insulin Homo sapiens 35-42 20151766-2 2010 STUDY DESIGN AND METHODS: Twenty-three subjects participated in this crossover study consisting of three treatment arms: delivering an insulin glulisine bolus by insulin pump 20 min prior to a meal ("PRE"), immediately before the meal ("START"), and 20 min after meal initiation ("POST"). glulisine 143-152 insulin Homo sapiens 135-142 20144398-1 2009 BACKGROUND: SoloSTAR (SOL; sanofi-aventis, Paris, France) is a prefilled insulin pen device for the injection of insulin glargine and insulin glulisine. glulisine 142-151 insulin Homo sapiens 73-80 19614946-1 2009 AIM: To evaluate the safety and efficacy of insulin glulisine (glulisine) with and without oral antidiabetic drugs (OAD; sulphonylurea or sulphonylurea + biguanide) relative to that of OAD alone in Japanese and Korean patients with inadequately controlled type 2 diabetes mellitus (T2DM). glulisine 52-61 insulin Homo sapiens 44-51 19614947-0 2009 Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus. glulisine 31-40 insulin Homo sapiens 23-30 19614947-1 2009 AIM: The rapid-acting insulin analogue insulin glulisine (glulisine) was compared with insulin lispro (lispro) for efficacy and safety in Japanese patients with type 1 diabetes mellitus (T1DM), using insulin glargine (glargine) as basal insulin. glulisine 47-56 insulin Homo sapiens 22-29 19614947-1 2009 AIM: The rapid-acting insulin analogue insulin glulisine (glulisine) was compared with insulin lispro (lispro) for efficacy and safety in Japanese patients with type 1 diabetes mellitus (T1DM), using insulin glargine (glargine) as basal insulin. glulisine 58-67 insulin Homo sapiens 22-29 21437124-0 2009 Insulin glulisine in the management of diabetes. glulisine 8-17 insulin Homo sapiens 0-7 21437124-1 2009 Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still relatively unknown. glulisine 8-17 insulin Homo sapiens 0-7 21437124-3 2009 Only properly randomized long-term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog. glulisine 65-74 insulin Homo sapiens 116-123 19480564-0 2009 Proliferative effect of Apidra (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells. glulisine 40-49 insulin Homo sapiens 32-39 19480564-0 2009 Proliferative effect of Apidra (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells. glulisine 40-49 insulin Homo sapiens 67-74 19480564-2 2009 We analysed the proliferative effect of the rapid-acting insulin analogue Apidra (insulin glulisine) on mammary epithelial cells. glulisine 90-99 insulin Homo sapiens 57-64 19193822-2 2009 DATA OVERVIEW: Rapid-acting insulin analogs (ie, aspart, lispro, glulisine) have a pharmacokinetic profile that mirrors endogenous insulin more closely than regular human insulin. glulisine 65-74 insulin Homo sapiens 28-35 19448209-1 2009 The insulin regimen of a Type 2 diabetic presenting for surgery had been changed recently from a 70/30 mixture of insulin aspart protamine and aspart to insulin detemir and insulin glulisine. glulisine 181-190 insulin Homo sapiens 4-11 19496630-4 2009 Insulin glulisine is effective when compared to other short- and rapid-acting insulins, demonstrating either noninferiority, no significant difference, or superiority in primary endpoints in studies involving patients with type 1 and type 2 diabetes. glulisine 8-17 insulin Homo sapiens 0-7 19496630-6 2009 Insulin glulisine is as effective as insulin lispro in patients with type 1 diabetes; however, there is a need for further, well designed head-to-head comparisons with insulin lispro in patients with type 2 diabetes and with insulin aspart in patients with type 1 or type 2 diabetes to fully establish the place of insulin glulisine in the management of diabetes. glulisine 8-17 insulin Homo sapiens 0-7 19496630-7 2009 Insulin glulisine has a flexible administration period, as it can be administered immediately before or after meals. glulisine 8-17 insulin Homo sapiens 0-7 19496630-9 2009 Thus, insulin glulisine is an effective and well tolerated option for the treatment of patients with type 1 and type 2 diabetes. glulisine 14-23 insulin Homo sapiens 6-13 19070911-0 2009 Insulin glulisine in the treatment of allergy to rapid acting insulin and its rapid acting analogs. glulisine 8-17 insulin Homo sapiens 0-7 19070911-0 2009 Insulin glulisine in the treatment of allergy to rapid acting insulin and its rapid acting analogs. glulisine 8-17 insulin Homo sapiens 62-69 19496630-0 2009 Insulin glulisine: a review of its use in the management of diabetes mellitus. glulisine 8-17 insulin Homo sapiens 0-7 19496630-1 2009 Insulin glulisine (Apidra) is a human insulin analogue approved for the improvement of glycaemic control in adults, adolescents and children with diabetes mellitus. glulisine 8-17 insulin Homo sapiens 0-7 19496630-1 2009 Insulin glulisine (Apidra) is a human insulin analogue approved for the improvement of glycaemic control in adults, adolescents and children with diabetes mellitus. glulisine 8-17 insulin Homo sapiens 38-45 19496630-3 2009 Insulin glulisine and insulin lispro have similar effects on glucose levels. glulisine 8-17 insulin Homo sapiens 0-7 19336657-0 2009 Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application. glulisine 8-17 insulin Homo sapiens 0-7 19336657-1 2009 OBJECTIVE: To evaluate the pharmacodynamic properties, efficacy, safety, and clinical application of insulin glulisine, a rapid-acting insulin analog, in the treatment of diabetes mellitus in ambulatory and hospitalized patients. glulisine 109-118 insulin Homo sapiens 101-108 19336657-1 2009 OBJECTIVE: To evaluate the pharmacodynamic properties, efficacy, safety, and clinical application of insulin glulisine, a rapid-acting insulin analog, in the treatment of diabetes mellitus in ambulatory and hospitalized patients. glulisine 109-118 insulin Homo sapiens 135-142 19336657-5 2009 DATA SYNTHESIS: Insulin glulisine is a rapid-acting insulin with relative equivalence in efficacy and safety to other short- and rapid-acting insulins. glulisine 24-33 insulin Homo sapiens 16-23 19336657-5 2009 DATA SYNTHESIS: Insulin glulisine is a rapid-acting insulin with relative equivalence in efficacy and safety to other short- and rapid-acting insulins. glulisine 24-33 insulin Homo sapiens 52-59 19336657-10 2009 CONCLUSIONS: Insulin glulisine is a safe and effective rapid-acting insulin analog for the treatment of adults with diabetes. glulisine 21-30 insulin Homo sapiens 13-20 19336657-10 2009 CONCLUSIONS: Insulin glulisine is a safe and effective rapid-acting insulin analog for the treatment of adults with diabetes. glulisine 21-30 insulin Homo sapiens 68-75 19216625-0 2009 Insulin glulisine: aspects of basal/bolus therapy for optimized treatment of diabetes mellitus. glulisine 8-17 insulin Homo sapiens 0-7 19216625-3 2009 METHODS: This review focuses on insulin glulisine in the basal-bolus approach. glulisine 40-49 insulin Homo sapiens 32-39 19216625-5 2009 RESULTS/CONCLUSION: Insulin glulisine offers a more rapid onset of action and shorter duration of action compared with regular human insulin. glulisine 28-37 insulin Homo sapiens 20-27 19120431-3 2009 The rapid-acting insulin analogues, lispro, aspart and glulisine, have a rapid onset of action and shorter duration of action because of changes to the B26-30 portion of insulin inhibiting formation of dimers and hexamers. glulisine 55-64 insulin Homo sapiens 17-24 19120431-3 2009 The rapid-acting insulin analogues, lispro, aspart and glulisine, have a rapid onset of action and shorter duration of action because of changes to the B26-30 portion of insulin inhibiting formation of dimers and hexamers. glulisine 55-64 insulin Homo sapiens 170-177 19193822-2 2009 DATA OVERVIEW: Rapid-acting insulin analogs (ie, aspart, lispro, glulisine) have a pharmacokinetic profile that mirrors endogenous insulin more closely than regular human insulin. glulisine 65-74 insulin Homo sapiens 131-138 19193822-2 2009 DATA OVERVIEW: Rapid-acting insulin analogs (ie, aspart, lispro, glulisine) have a pharmacokinetic profile that mirrors endogenous insulin more closely than regular human insulin. glulisine 65-74 insulin Homo sapiens 131-138 19040645-1 2008 AIM: To investigate whether the addition of a single bolus of insulin glulisine (glulisine), administered at either breakfast or main mealtime, in combination with basal insulin glargine (glargine) and oral antidiabetic drugs (OADs), provides equivalent glycaemic control in patients with type 2 diabetes, irrespective of the time of glulisine injection. glulisine 70-79 insulin Homo sapiens 62-69 19436644-1 2009 The insulin analogs lispro, aspart, and glulisine are the only commercially available rapid-acting insulins to treat diabetes. glulisine 40-49 insulin Homo sapiens 4-11 18715206-9 2008 Insulin glulisine doses delivered were 4.98 (0.20), 14.87 (0.29), and 29.67 (0.34) units for 5, 15, and 30 units, respectively. glulisine 8-17 insulin Homo sapiens 0-7 18715525-1 2008 OBJECTIVE: SoloSTAR (SR) is a new pre-filled insulin pen device for administration of insulin glargine and insulin glulisine. glulisine 115-124 insulin Homo sapiens 45-52 17764465-0 2008 Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study. glulisine 8-17 insulin Homo sapiens 0-7 18577159-2 2008 For patients close to but not at target, the management of postprandial glucose excursions with a rapid-acting insulin, such as insulin glulisine, can provide further improvements in glycaemic control. glulisine 136-145 insulin Homo sapiens 111-118 18577159-2 2008 For patients close to but not at target, the management of postprandial glucose excursions with a rapid-acting insulin, such as insulin glulisine, can provide further improvements in glycaemic control. glulisine 136-145 insulin Homo sapiens 128-135 19885209-8 2008 Over the whole of the 5-day infusion period, the probabilities of overall occlusion for each insulin were 40.9% [28 to 55%, 95% confidence interval (CI)] for glulisine, 9.2% (4 to 19.5%, 95% CI) for aspart, and 15.7% (8.1 to 28.1%, 95% CI) for lispro. glulisine 158-167 insulin Homo sapiens 93-100 18268067-1 2008 OBJECTIVE: To investigate the effect of insulin glulisine on postprandial microvascular blood flow in type 2 diabetes. glulisine 48-57 insulin Homo sapiens 40-47 18268067-2 2008 RESEARCH DESIGN AND METHODS: A total of 15 patients with type 2 diabetes received insulin glulisine or human insulin before a liquid meal test. glulisine 90-99 insulin Homo sapiens 82-89 18268067-4 2008 RESULTS: Insulin glulisine injections resulted in higher postprandial insulin levels (means +/- SEM area under the curve [AUC](0-120) 51.0 +/- 6.8 vs. 38.2 +/- 5.4 mU/l; P = 0.004), while plasma glucose (AUC(0-240) 158 +/- 9 vs. 180 +/- 9 mg/dl; P < 0.05) and intact proinsulin (AUC(0-240) 26.2 +/- 3.5 vs. 31.2 +/- 4.3 pmol/l; P = 0.002) were lower. glulisine 17-26 insulin Homo sapiens 9-16 18268067-4 2008 RESULTS: Insulin glulisine injections resulted in higher postprandial insulin levels (means +/- SEM area under the curve [AUC](0-120) 51.0 +/- 6.8 vs. 38.2 +/- 5.4 mU/l; P = 0.004), while plasma glucose (AUC(0-240) 158 +/- 9 vs. 180 +/- 9 mg/dl; P < 0.05) and intact proinsulin (AUC(0-240) 26.2 +/- 3.5 vs. 31.2 +/- 4.3 pmol/l; P = 0.002) were lower. glulisine 17-26 insulin Homo sapiens 70-77 18268067-4 2008 RESULTS: Insulin glulisine injections resulted in higher postprandial insulin levels (means +/- SEM area under the curve [AUC](0-120) 51.0 +/- 6.8 vs. 38.2 +/- 5.4 mU/l; P = 0.004), while plasma glucose (AUC(0-240) 158 +/- 9 vs. 180 +/- 9 mg/dl; P < 0.05) and intact proinsulin (AUC(0-240) 26.2 +/- 3.5 vs. 31.2 +/- 4.3 pmol/l; P = 0.002) were lower. glulisine 17-26 insulin Homo sapiens 270-280 18268067-5 2008 Microvascular blood flow increased after insulin glulisine injection (27.9 +/- 3.1 to 51.7 +/- 9.9 arbitrary units [AU]; P < 0.05), while only a minor increase was found during human insulin (27.9 +/- 3.1 to 34.4 +/- 7.8 AU; not significant). glulisine 49-58 insulin Homo sapiens 41-48 18268067-6 2008 Asymmetric dimethylarginine and nitrotyrosine levels were reduced after insulin glulisine (P < 0.05). glulisine 80-89 insulin Homo sapiens 72-79 18268067-7 2008 CONCLUSIONS: Insulin glulisine is superior to human insulin in restoring postprandial metabolic and microvascular physiology. glulisine 21-30 insulin Homo sapiens 13-20 18615401-2 2008 Shortacting insulin (lispro, aspart and glulisine) and long-acting insulin (glargine and detemir) have been developed for the management of diabetes. glulisine 40-49 insulin Homo sapiens 12-19 17675541-0 2007 Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. glulisine 38-47 insulin Homo sapiens 30-37 18164094-5 2008 Mean concentrations of insulin analogue were significantly higher post-meal with glulisine (p<0.01 for all). glulisine 81-90 insulin Homo sapiens 23-30 18164094-9 2008 Significantly faster absorption with higher and sustained post-meal levels of insulin analogue was achieved at every meal with glulisine versus lispro. glulisine 127-136 insulin Homo sapiens 78-85 18698880-4 2008 Insulin glulisine is a new rapid-acting analogue and has characteristics nearly identical to those of its predecessors. glulisine 8-17 insulin Homo sapiens 0-7 18034606-1 2007 BACKGROUND: This study was designed to evaluate the stability properties of the marketed insulin aspart (IAsp) and insulin glulisine (IGlu) products during simulated continuous subcutaneous insulin infusion (CSII) for up to 10 days. glulisine 123-132 insulin Homo sapiens 115-122 18414816-2 2008 This article describes how insulin analogues (insulins lispro, aspart, glulisine, glargine and detemir) may have a role to play in overcoming barriers to insulin acceptance and improving adherence with therapy, and examines their cost-effectiveness as determined in published studies. glulisine 71-80 insulin Homo sapiens 27-34 18414816-2 2008 This article describes how insulin analogues (insulins lispro, aspart, glulisine, glargine and detemir) may have a role to play in overcoming barriers to insulin acceptance and improving adherence with therapy, and examines their cost-effectiveness as determined in published studies. glulisine 71-80 insulin Homo sapiens 46-53 18465353-3 2008 The benefits of rapid-acting analogues (lispro, aspart and glulisine have similar pharmacodynamic effects) compared with non-modified human regular insulin, are: (a) lower 1- and 2-h post-prandial blood glucose; (b) lower risk of late post-prandial hypoglycaemia (and therefore lower BG variability); (c) better quality of life (greater flexibility in timing and dosing of insulin). glulisine 59-68 insulin Homo sapiens 373-380 18465359-7 2008 The patent-protected insulin analogues Lispro, Glulisine, Aspart, Glargine and Detemir are artificial insulin derivatives with altered biological responses compared to natural insulin (e.g. divergent insulin and /or IGF-1 receptor-binding characteristics, signalling patterns, and mitogenicity). glulisine 47-56 insulin Homo sapiens 21-28 18465359-7 2008 The patent-protected insulin analogues Lispro, Glulisine, Aspart, Glargine and Detemir are artificial insulin derivatives with altered biological responses compared to natural insulin (e.g. divergent insulin and /or IGF-1 receptor-binding characteristics, signalling patterns, and mitogenicity). glulisine 47-56 insulin Homo sapiens 102-109 18465359-7 2008 The patent-protected insulin analogues Lispro, Glulisine, Aspart, Glargine and Detemir are artificial insulin derivatives with altered biological responses compared to natural insulin (e.g. divergent insulin and /or IGF-1 receptor-binding characteristics, signalling patterns, and mitogenicity). glulisine 47-56 insulin Homo sapiens 102-109 18465359-7 2008 The patent-protected insulin analogues Lispro, Glulisine, Aspart, Glargine and Detemir are artificial insulin derivatives with altered biological responses compared to natural insulin (e.g. divergent insulin and /or IGF-1 receptor-binding characteristics, signalling patterns, and mitogenicity). glulisine 47-56 insulin Homo sapiens 102-109 18076215-0 2008 Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. glulisine 58-67 insulin Homo sapiens 50-57 18076215-1 2008 Insulin glulisine injection [3(B)-Lys, 29(B)-Glu-human insulin] is the newest human insulin analogue product for the control of mealtime blood sugar. glulisine 8-17 insulin Homo sapiens 0-7 18076215-1 2008 Insulin glulisine injection [3(B)-Lys, 29(B)-Glu-human insulin] is the newest human insulin analogue product for the control of mealtime blood sugar. glulisine 8-17 insulin Homo sapiens 55-62 18076215-1 2008 Insulin glulisine injection [3(B)-Lys, 29(B)-Glu-human insulin] is the newest human insulin analogue product for the control of mealtime blood sugar. glulisine 8-17 insulin Homo sapiens 84-91 18076215-2 2008 As with insulin aspart and insulin lispro products, the insulin glulisine product displays faster absorption and onset of action, with a shorter duration of action than that of regular human insulin. glulisine 64-73 insulin Homo sapiens 8-15 18076215-2 2008 As with insulin aspart and insulin lispro products, the insulin glulisine product displays faster absorption and onset of action, with a shorter duration of action than that of regular human insulin. glulisine 64-73 insulin Homo sapiens 27-34 18076215-3 2008 The modifications of the amino acid sequence at positions 3 and 29 in the B chain of human insulin simultaneously provide stability to the molecular structure and render the insulin glulisine molecule less likely to self-associate, compared with human insulin, while still allowing the formation of dimers at pharmaceutical concentrations. glulisine 182-191 insulin Homo sapiens 91-98 18076215-3 2008 The modifications of the amino acid sequence at positions 3 and 29 in the B chain of human insulin simultaneously provide stability to the molecular structure and render the insulin glulisine molecule less likely to self-associate, compared with human insulin, while still allowing the formation of dimers at pharmaceutical concentrations. glulisine 182-191 insulin Homo sapiens 174-181 18076215-3 2008 The modifications of the amino acid sequence at positions 3 and 29 in the B chain of human insulin simultaneously provide stability to the molecular structure and render the insulin glulisine molecule less likely to self-associate, compared with human insulin, while still allowing the formation of dimers at pharmaceutical concentrations. glulisine 182-191 insulin Homo sapiens 174-181 18076215-4 2008 Unlike other insulin analogue products, this allows for a viable drug product in the absence of hexamer-promoting zinc and, thus, provides immediate availability of insulin glulisine molecules at the injection site for absorption. glulisine 173-182 insulin Homo sapiens 13-20 18076215-4 2008 Unlike other insulin analogue products, this allows for a viable drug product in the absence of hexamer-promoting zinc and, thus, provides immediate availability of insulin glulisine molecules at the injection site for absorption. glulisine 173-182 insulin Homo sapiens 165-172 18076215-5 2008 Pharmacokinetic studies with insulin glulisine have shown an absorption profile with a peak insulin concentration approximately twice that of regular human insulin, which is reached in approximately half the time. glulisine 37-46 insulin Homo sapiens 29-36 18076215-5 2008 Pharmacokinetic studies with insulin glulisine have shown an absorption profile with a peak insulin concentration approximately twice that of regular human insulin, which is reached in approximately half the time. glulisine 37-46 insulin Homo sapiens 92-99 18076215-5 2008 Pharmacokinetic studies with insulin glulisine have shown an absorption profile with a peak insulin concentration approximately twice that of regular human insulin, which is reached in approximately half the time. glulisine 37-46 insulin Homo sapiens 92-99 18076215-6 2008 Dose proportionality in early, maximum and total exposure is observed for insulin glulisine over the therapeutic relevant dose range up to 0.4 U/kg. glulisine 82-91 insulin Homo sapiens 74-81 18076215-7 2008 The pharmacodynamic profile of insulin glulisine reflects the absorption kinetics by demonstrating a greater rate of glucose utilization, which is completed earlier and at equipotency on a molar base compared with regular human insulin. glulisine 39-48 insulin Homo sapiens 31-38 18076215-8 2008 Dose-proportionality in glucose utilization has been established for insulin glulisine in patients with type 1 diabetes mellitus in the dose range of 0.075-0.15 U/kg, and a less than dose-proportional increase above 0.15 U/kg, indicating saturation of insulin action in general. glulisine 77-86 insulin Homo sapiens 69-76 18076215-9 2008 The rapid absorption and action of insulin glulisine show similar low intrasubject variability compared with insulin lispro and regular human insulin when given repeatedly, and have been confirmed in healthy subjects of different body mass indices (BMIs) and ethnic groups, as well as adults and children with type 1 and type 2 diabetes. glulisine 43-52 insulin Homo sapiens 35-42 18076215-10 2008 Furthermore, the early insulin exposure and action of insulin glulisine were slightly -- but consistently -- greater than those of insulin lispro in healthy volunteers across a wide range of BMIs.Meal studies in patients with type 1 diabetes show that insulin glulisine provides better postprandial blood glucose control than regular human insulin when administered immediately pre-meal, and equivalent control when given after the meal. glulisine 62-71 insulin Homo sapiens 23-30 18076215-10 2008 Furthermore, the early insulin exposure and action of insulin glulisine were slightly -- but consistently -- greater than those of insulin lispro in healthy volunteers across a wide range of BMIs.Meal studies in patients with type 1 diabetes show that insulin glulisine provides better postprandial blood glucose control than regular human insulin when administered immediately pre-meal, and equivalent control when given after the meal. glulisine 62-71 insulin Homo sapiens 54-61 18076215-10 2008 Furthermore, the early insulin exposure and action of insulin glulisine were slightly -- but consistently -- greater than those of insulin lispro in healthy volunteers across a wide range of BMIs.Meal studies in patients with type 1 diabetes show that insulin glulisine provides better postprandial blood glucose control than regular human insulin when administered immediately pre-meal, and equivalent control when given after the meal. glulisine 62-71 insulin Homo sapiens 54-61 18076215-10 2008 Furthermore, the early insulin exposure and action of insulin glulisine were slightly -- but consistently -- greater than those of insulin lispro in healthy volunteers across a wide range of BMIs.Meal studies in patients with type 1 diabetes show that insulin glulisine provides better postprandial blood glucose control than regular human insulin when administered immediately pre-meal, and equivalent control when given after the meal. glulisine 62-71 insulin Homo sapiens 54-61 18076215-10 2008 Furthermore, the early insulin exposure and action of insulin glulisine were slightly -- but consistently -- greater than those of insulin lispro in healthy volunteers across a wide range of BMIs.Meal studies in patients with type 1 diabetes show that insulin glulisine provides better postprandial blood glucose control than regular human insulin when administered immediately pre-meal, and equivalent control when given after the meal. glulisine 62-71 insulin Homo sapiens 54-61 18076215-10 2008 Furthermore, the early insulin exposure and action of insulin glulisine were slightly -- but consistently -- greater than those of insulin lispro in healthy volunteers across a wide range of BMIs.Meal studies in patients with type 1 diabetes show that insulin glulisine provides better postprandial blood glucose control than regular human insulin when administered immediately pre-meal, and equivalent control when given after the meal. glulisine 260-269 insulin Homo sapiens 54-61 18076215-10 2008 Furthermore, the early insulin exposure and action of insulin glulisine were slightly -- but consistently -- greater than those of insulin lispro in healthy volunteers across a wide range of BMIs.Meal studies in patients with type 1 diabetes show that insulin glulisine provides better postprandial blood glucose control than regular human insulin when administered immediately pre-meal, and equivalent control when given after the meal. glulisine 260-269 insulin Homo sapiens 54-61 18076215-10 2008 Furthermore, the early insulin exposure and action of insulin glulisine were slightly -- but consistently -- greater than those of insulin lispro in healthy volunteers across a wide range of BMIs.Meal studies in patients with type 1 diabetes show that insulin glulisine provides better postprandial blood glucose control than regular human insulin when administered immediately pre-meal, and equivalent control when given after the meal. glulisine 260-269 insulin Homo sapiens 54-61 18076215-10 2008 Furthermore, the early insulin exposure and action of insulin glulisine were slightly -- but consistently -- greater than those of insulin lispro in healthy volunteers across a wide range of BMIs.Meal studies in patients with type 1 diabetes show that insulin glulisine provides better postprandial blood glucose control than regular human insulin when administered immediately pre-meal, and equivalent control when given after the meal. glulisine 260-269 insulin Homo sapiens 54-61 18076215-11 2008 In a study in patients with type 2 diabetes, the overall postprandial blood glucose excursions were lower with insulin glulisine than with insulin lispro. glulisine 119-128 insulin Homo sapiens 111-118 18076215-12 2008 Therefore, by virtue of its primary structure, insulin glulisine demonstrates both low self-association in solution and stability for a viable insulin product in the absence of zinc, thereby maintaining immediate availability for absorption after subcutaneous injection. glulisine 55-64 insulin Homo sapiens 47-54 18076215-12 2008 Therefore, by virtue of its primary structure, insulin glulisine demonstrates both low self-association in solution and stability for a viable insulin product in the absence of zinc, thereby maintaining immediate availability for absorption after subcutaneous injection. glulisine 55-64 insulin Homo sapiens 143-150 17561792-1 2007 BACKGROUND: Absorption rates of the phosphate-buffered insulin analogs aspart, lispro, and glulisine prevail over that of regular human insulin. glulisine 91-100 insulin Homo sapiens 55-62 17703168-7 2007 Inhaled insulin showed similar pharmacokinetic and glucodynamic behavior like that of subcutaneously administered rapid acting human insulin analogues like aspart, lispro and glulisine. glulisine 175-184 insulin Homo sapiens 8-15 17703168-7 2007 Inhaled insulin showed similar pharmacokinetic and glucodynamic behavior like that of subcutaneously administered rapid acting human insulin analogues like aspart, lispro and glulisine. glulisine 175-184 insulin Homo sapiens 133-140 17593235-0 2007 Insulin glulisine: a faster onset of action compared with insulin lispro. glulisine 8-17 insulin Homo sapiens 0-7 17113676-0 2007 Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. glulisine 8-17 insulin Homo sapiens 0-7 17113676-1 2007 INTRODUCTION: Insulin glulisine (glulisine) was evaluated versus regular human insulin (RHI) in Type 2 diabetes (T2DM) patients. glulisine 22-31 insulin Homo sapiens 14-21 17113676-1 2007 INTRODUCTION: Insulin glulisine (glulisine) was evaluated versus regular human insulin (RHI) in Type 2 diabetes (T2DM) patients. glulisine 33-42 insulin Homo sapiens 14-21 17703632-11 2007 The safety and tolerability profile of insulin glulisine is also comparable to that of insulin lispro or RHI in type 1 or 2 DM and it has been shown to be as safe and effective when used in a continuous subcutaneous insulin infusion (CSII). glulisine 47-56 insulin Homo sapiens 39-46 17335413-1 2007 SoloStar (sanofi-aventis) is a new, disposable insulin pen for the administration of insulin glargine (Lantus, sanofi-aventis) or insulin glulisine (Apidra, sanofi-aventis). glulisine 138-147 insulin Homo sapiens 47-54 17316105-0 2007 Insulin glulisine complementing basal insulins: a review of structure and activity. glulisine 8-17 insulin Homo sapiens 0-7 17316105-2 2007 Insulin glulisine (3(B)Lys29(B) Glu-human insulin) is a new fast-acting analog that provides absorption and onset of action more rapidly with a shorter duration of action compared with regular human insulin, and thus better resembles physiologic mealtime insulin requirements. glulisine 8-17 insulin Homo sapiens 0-7 17316105-2 2007 Insulin glulisine (3(B)Lys29(B) Glu-human insulin) is a new fast-acting analog that provides absorption and onset of action more rapidly with a shorter duration of action compared with regular human insulin, and thus better resembles physiologic mealtime insulin requirements. glulisine 8-17 insulin Homo sapiens 42-49 17316105-2 2007 Insulin glulisine (3(B)Lys29(B) Glu-human insulin) is a new fast-acting analog that provides absorption and onset of action more rapidly with a shorter duration of action compared with regular human insulin, and thus better resembles physiologic mealtime insulin requirements. glulisine 8-17 insulin Homo sapiens 199-206 17316105-2 2007 Insulin glulisine (3(B)Lys29(B) Glu-human insulin) is a new fast-acting analog that provides absorption and onset of action more rapidly with a shorter duration of action compared with regular human insulin, and thus better resembles physiologic mealtime insulin requirements. glulisine 8-17 insulin Homo sapiens 199-206 17316105-3 2007 Insulin glulisine has been designed to exhibit intrinsic stability while maintaining rapid deployment of insulin monomers. glulisine 8-17 insulin Homo sapiens 0-7 17316105-3 2007 Insulin glulisine has been designed to exhibit intrinsic stability while maintaining rapid deployment of insulin monomers. glulisine 8-17 insulin Homo sapiens 105-112 17316105-4 2007 Pharmacokinetic and pharmacodynamic profiling of insulin glulisine in healthy subjects and patients with type 1 and type 2 diabetes not only confirms the rapid absorption and fast action of insulin glulisine compared with human insulin, but also provides evidence that the unique drug formulation may offer additional benefits. glulisine 57-66 insulin Homo sapiens 49-56 17316105-4 2007 Pharmacokinetic and pharmacodynamic profiling of insulin glulisine in healthy subjects and patients with type 1 and type 2 diabetes not only confirms the rapid absorption and fast action of insulin glulisine compared with human insulin, but also provides evidence that the unique drug formulation may offer additional benefits. glulisine 57-66 insulin Homo sapiens 190-197 17316105-4 2007 Pharmacokinetic and pharmacodynamic profiling of insulin glulisine in healthy subjects and patients with type 1 and type 2 diabetes not only confirms the rapid absorption and fast action of insulin glulisine compared with human insulin, but also provides evidence that the unique drug formulation may offer additional benefits. glulisine 57-66 insulin Homo sapiens 190-197 17316105-4 2007 Pharmacokinetic and pharmacodynamic profiling of insulin glulisine in healthy subjects and patients with type 1 and type 2 diabetes not only confirms the rapid absorption and fast action of insulin glulisine compared with human insulin, but also provides evidence that the unique drug formulation may offer additional benefits. glulisine 198-207 insulin Homo sapiens 49-56 17316105-4 2007 Pharmacokinetic and pharmacodynamic profiling of insulin glulisine in healthy subjects and patients with type 1 and type 2 diabetes not only confirms the rapid absorption and fast action of insulin glulisine compared with human insulin, but also provides evidence that the unique drug formulation may offer additional benefits. glulisine 198-207 insulin Homo sapiens 190-197 17316105-4 2007 Pharmacokinetic and pharmacodynamic profiling of insulin glulisine in healthy subjects and patients with type 1 and type 2 diabetes not only confirms the rapid absorption and fast action of insulin glulisine compared with human insulin, but also provides evidence that the unique drug formulation may offer additional benefits. glulisine 198-207 insulin Homo sapiens 190-197 17316105-5 2007 Insulin glulisine complements insulin glargine (21(A)-Gly30(Ba)-L-Arg-30(Bb)-L-Arg-human insulin), the first long-acting basal insulin analog that displays a smoothed time-action profile with a 24-h duration of action. glulisine 8-17 insulin Homo sapiens 0-7 17316095-0 2007 Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion. glulisine 44-53 insulin Homo sapiens 36-43 17316095-0 2007 Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion. glulisine 44-53 insulin Homo sapiens 36-43 17181446-0 2007 Insulin glulisine: efficacy and safety compared with other rapid-acting insulin analogues. glulisine 8-17 insulin Homo sapiens 0-7 17181446-1 2007 Glulisine insulin is the latest addition to the class of rapid-acting insulin analogues. glulisine 0-9 insulin Homo sapiens 10-17 17181446-1 2007 Glulisine insulin is the latest addition to the class of rapid-acting insulin analogues. glulisine 0-9 insulin Homo sapiens 70-77 17344794-9 2007 The ultrashort acting analogue insulins are insulin lispro, insulin aspart and insulin glulisine. glulisine 87-96 insulin Homo sapiens 31-38 17703632-6 2007 Insulin glulisine (Apidra) is a rapid-acting insulin analogue created by substituting lysine for asparagine at position B3 and glutamic acid for lysine at position B29 on the B chain of human insulin. glulisine 8-17 insulin Homo sapiens 0-7 17703632-6 2007 Insulin glulisine (Apidra) is a rapid-acting insulin analogue created by substituting lysine for asparagine at position B3 and glutamic acid for lysine at position B29 on the B chain of human insulin. glulisine 8-17 insulin Homo sapiens 45-52 17703632-6 2007 Insulin glulisine (Apidra) is a rapid-acting insulin analogue created by substituting lysine for asparagine at position B3 and glutamic acid for lysine at position B29 on the B chain of human insulin. glulisine 8-17 insulin Homo sapiens 192-199 17703632-7 2007 The quick absorption of insulin glulisine more closely reproduces physiologic first-phase insulin secretion and its rapid acting profile is maintained across patient subtypes. glulisine 32-41 insulin Homo sapiens 24-31 17703632-9 2007 Efficacy is maintained even when insulin glulisine is administered post-meal. glulisine 41-50 insulin Homo sapiens 33-40 17703632-12 2007 In summary, insulin glulisine is a safe, effective, and well tolerated rapid-acting insulin analogue across all BMIs and a worthy option for prandial glucose control in type 1 or 2 DM. glulisine 20-29 insulin Homo sapiens 12-19 17703632-12 2007 In summary, insulin glulisine is a safe, effective, and well tolerated rapid-acting insulin analogue across all BMIs and a worthy option for prandial glucose control in type 1 or 2 DM. glulisine 20-29 insulin Homo sapiens 84-91 16873785-0 2006 Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. glulisine 38-47 insulin Homo sapiens 30-37 16873785-1 2006 OBJECTIVE: Insulin glulisine, a rapid-acting insulin analog, provides prandial insulin replacement. glulisine 19-28 insulin Homo sapiens 11-18 16873785-1 2006 OBJECTIVE: Insulin glulisine, a rapid-acting insulin analog, provides prandial insulin replacement. glulisine 19-28 insulin Homo sapiens 45-52 16873785-1 2006 OBJECTIVE: Insulin glulisine, a rapid-acting insulin analog, provides prandial insulin replacement. glulisine 19-28 insulin Homo sapiens 79-86 16873785-7 2006 h/dl, maximum blood glucose concentration (180 vs. 209 mg/dl), and less time to maximum blood glucose excursion (48 vs. 70 min) were seen with immediately premeal insulin glulisine versus immediately premeal RHI. glulisine 171-180 insulin Homo sapiens 163-170 16873785-8 2006 The maximum serum concentration of insulin glulisine was almost double that of RHI (82 vs. 45 microU/ml), achieved in approximately half the time (55 vs. 97 min). glulisine 43-52 insulin Homo sapiens 35-42 16873785-10 2006 CONCLUSIONS: Insulin glulisine renders postprandial glucose disposal closer to physiologic requirements compared with RHI and enables appropriate timing of prandial insulin administration. glulisine 21-30 insulin Homo sapiens 13-20 16873785-10 2006 CONCLUSIONS: Insulin glulisine renders postprandial glucose disposal closer to physiologic requirements compared with RHI and enables appropriate timing of prandial insulin administration. glulisine 21-30 insulin Homo sapiens 165-172 16706558-4 2006 In patients with type 2 diabetes, insulin glulisine induced significantly greater reductions in HbA(1c) levels and 2-hour post-breakfast and post-dinner blood glucose levels than RHI over a period of 26 weeks. glulisine 42-51 insulin Homo sapiens 34-41 16823727-0 2006 Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. glulisine 18-27 insulin Homo sapiens 10-17 16823727-9 2006 This study supports the safety of insulin glulisine in continuous subcutaneous insulin infusion administered via an external pump in type 1 diabetes. glulisine 42-51 insulin Homo sapiens 34-41 16823727-9 2006 This study supports the safety of insulin glulisine in continuous subcutaneous insulin infusion administered via an external pump in type 1 diabetes. glulisine 42-51 insulin Homo sapiens 79-86 16569928-6 2006 Insulin glulisine is a short acting analogue with a rapid onset of action. glulisine 8-17 insulin Homo sapiens 0-7 30290463-0 2006 Rapid-acting insulin glulisine: a new tool for postprandial glucose control. glulisine 21-30 insulin Homo sapiens 13-20 30290463-1 2006 Insulin glulisine (Apidra , Sanofi-Aventis) is a novel, rapid-acting insulin analog that replicates normal mealtime insulin secretion more closely than regular human insulin. glulisine 8-17 insulin Homo sapiens 0-7 30290463-1 2006 Insulin glulisine (Apidra , Sanofi-Aventis) is a novel, rapid-acting insulin analog that replicates normal mealtime insulin secretion more closely than regular human insulin. glulisine 8-17 insulin Homo sapiens 69-76 30290463-1 2006 Insulin glulisine (Apidra , Sanofi-Aventis) is a novel, rapid-acting insulin analog that replicates normal mealtime insulin secretion more closely than regular human insulin. glulisine 8-17 insulin Homo sapiens 116-123 30290463-1 2006 Insulin glulisine (Apidra , Sanofi-Aventis) is a novel, rapid-acting insulin analog that replicates normal mealtime insulin secretion more closely than regular human insulin. glulisine 8-17 insulin Homo sapiens 116-123 30290463-2 2006 Compared with regular human insulin, glulisine has a more rapid onset of action and shorter duration of effect, affording greater flexibility in the timing and content of meals. glulisine 37-46 insulin Homo sapiens 28-35 30290463-5 2006 Insulin glulisine is safe when used for pump therapy and its rapid-acting properties are maintained consistently across patient types and body mass indices, making it an effective and versatile tool for postprandial glucose control. glulisine 8-17 insulin Homo sapiens 0-7 16706558-0 2006 Insulin glulisine. glulisine 8-17 insulin Homo sapiens 0-7 16706558-1 2006 Insulin glulisine is a rapid-acting human insulin analogue that has a faster onset of action and shorter duration of action than regular human insulin (RHI) in patients with type 1 or 2 diabetes mellitus and is efficacious in controlling prandial blood glucose levels in these patients. glulisine 8-17 insulin Homo sapiens 0-7 16706558-1 2006 Insulin glulisine is a rapid-acting human insulin analogue that has a faster onset of action and shorter duration of action than regular human insulin (RHI) in patients with type 1 or 2 diabetes mellitus and is efficacious in controlling prandial blood glucose levels in these patients. glulisine 8-17 insulin Homo sapiens 42-49 16706558-2 2006 In large, well designed trials in patients with type 1 diabetes, insulin glulisine demonstrated a similar degree of glycaemic control, as measured by glycosylated haemoglobin (HbA(1c)) levels, to RHI after 12 weeks and insulin lispro after 26 weeks. glulisine 73-82 insulin Homo sapiens 65-72 16706558-5 2006 Insulin glulisine was generally well tolerated by patients with type 1 or 2 diabetes and had a similar safety profile to insulin lispro or RHI. glulisine 8-17 insulin Homo sapiens 0-7 16706558-3 2006 Pre-meal insulin glulisine was also more effective than RHI at controlling 2-hour post-prandial glucose excursions in patients with type 1 or 2 diabetes over a period of 12 weeks. glulisine 17-26 insulin Homo sapiens 9-16 16706559-0 2006 Insulin glulisine: viewpoints. glulisine 8-17 insulin Homo sapiens 0-7 23101062-1 2005 In this text, the term "rapid-acting insulin analogues" (or "RAIs") refers to all currently approved and available preparations of this type in Germany: insulin aspart, insulin glulisine, and insulin lispro. glulisine 177-186 insulin Homo sapiens 37-44 17028476-10 2006 Insulin glulisine is the most recently approved rapid-acting insulin analog. glulisine 8-17 insulin Homo sapiens 0-7 17028476-10 2006 Insulin glulisine is the most recently approved rapid-acting insulin analog. glulisine 8-17 insulin Homo sapiens 61-68 17028476-12 2006 Moreover, the pharmacokinetics of insulin glulisine does not depend on the amount of subcutaneous fat. glulisine 42-51 insulin Homo sapiens 34-41 16510354-0 2006 Insulin glulisine--a comprehensive preclinical evaluation. glulisine 8-17 insulin Homo sapiens 0-7 16510354-10 2006 Glulisine, Asp(B10), and RHI showed similar insulin receptor-association kinetics; however, Asp(B10) revealed increased insulin receptor affinity. glulisine 0-9 insulin Homo sapiens 44-51 16123473-1 2005 OBJECTIVE: The aim of this study was to investigate the pharmacokinetics, postprandial blood glucose excursions, and safety of insulin glulisine as compared with regular human insulin (RHI), both administered immediately before meals in pediatric patients with type 1 diabetes. glulisine 135-144 insulin Homo sapiens 127-134 16308840-0 2005 Efficacy and safety of insulin glulisine in patients with type 1 diabetes. glulisine 31-40 insulin Homo sapiens 23-30 16308840-1 2005 Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting time-action profile, has been developed to fulfil the mealtime (bolus) insulin requirement in patients with diabetes. glulisine 8-17 insulin Homo sapiens 0-7 16308840-1 2005 Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting time-action profile, has been developed to fulfil the mealtime (bolus) insulin requirement in patients with diabetes. glulisine 8-17 insulin Homo sapiens 39-46 16308840-1 2005 Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting time-action profile, has been developed to fulfil the mealtime (bolus) insulin requirement in patients with diabetes. glulisine 8-17 insulin Homo sapiens 147-154 16308840-1 2005 Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting time-action profile, has been developed to fulfil the mealtime (bolus) insulin requirement in patients with diabetes. glulisine 19-28 insulin Homo sapiens 0-7 16308840-1 2005 Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting time-action profile, has been developed to fulfil the mealtime (bolus) insulin requirement in patients with diabetes. glulisine 19-28 insulin Homo sapiens 39-46 16123473-0 2005 Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. glulisine 66-75 insulin Homo sapiens 58-65 16308840-1 2005 Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting time-action profile, has been developed to fulfil the mealtime (bolus) insulin requirement in patients with diabetes. glulisine 19-28 insulin Homo sapiens 147-154 16308840-5 2005 The basal insulin dose was relatively unchanged from baseline in the glulisine group but increased in the lispro group (glulisine: 0.12 IU vs. lispro: 1.82 IU; p = 0.0001). glulisine 120-129 insulin Homo sapiens 10-17 16308840-6 2005 As a consequence, total daily insulin dose decreased in the glulisine group but increased in the lispro group (glulisine: -0.86 IU vs. lispro: 1.01 IU; p = 0.0123). glulisine 60-69 insulin Homo sapiens 30-37 16030168-1 2005 CONTEXT: The insulin analog LysB3,GluB29-insulin (glulisine) displays accelerated in vivo bioavailability compared with native insulin. glulisine 50-59 insulin Homo sapiens 13-20 16030168-1 2005 CONTEXT: The insulin analog LysB3,GluB29-insulin (glulisine) displays accelerated in vivo bioavailability compared with native insulin. glulisine 50-59 insulin Homo sapiens 41-48 16030168-8 2005 RESULTS: Insulin and glulisine were comparable in their ability to displace insulin binding. glulisine 21-30 insulin Homo sapiens 76-83 16123473-3 2005 The blood glucose of fasting patients was stabilized with intravenous insulin, following which patients received 0.15 IU/kg of subcutaneously injected insulin glulisine or RHI 2 min before a weight-adjusted standardized liquid meal. glulisine 159-168 insulin Homo sapiens 151-158 16123473-5 2005 Both time to maximum insulin concentration (54 vs. 66 min) and mean residence time (88 vs. 137 min, P < 0.05) were shorter with insulin glulisine versus RHI. glulisine 139-148 insulin Homo sapiens 21-28 16123473-5 2005 Both time to maximum insulin concentration (54 vs. 66 min) and mean residence time (88 vs. 137 min, P < 0.05) were shorter with insulin glulisine versus RHI. glulisine 139-148 insulin Homo sapiens 131-138 16123473-6 2005 Postprandial glucose excursions after insulin glulisine were lower than after RHI (glucose AUC(0-6h) 641 vs. 801 mg.h(-1).dl(-1), P < 0.05). glulisine 46-55 insulin Homo sapiens 38-45 16123473-8 2005 Insulin glulisine was safe and well tolerated. glulisine 8-17 insulin Homo sapiens 0-7 16123473-9 2005 CONCLUSIONS: The rapid-acting properties of insulin glulisine that have been previously demonstrated in adults are also observed in children and adolescents with type 1 diabetes. glulisine 52-61 insulin Homo sapiens 44-51 16123473-10 2005 Further, these initial data indicate that insulin glulisine is safe and well tolerated in this patient population. glulisine 50-59 insulin Homo sapiens 42-49 15934890-0 2005 Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. glulisine 8-17 insulin Homo sapiens 0-7 16151977-0 2005 Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. glulisine 8-17 insulin Homo sapiens 0-7 16151977-0 2005 Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. glulisine 8-17 insulin Homo sapiens 38-45 16151977-1 2005 AIMS/HYPOTHESIS: This study compared the pharmacokinetics and pharmacodynamics of insulin glulisine, insulin lispro, and regular human insulin in obese subjects. glulisine 90-99 insulin Homo sapiens 82-89 16151977-5 2005 RESULTS: Insulin glulisine and insulin lispro had more rapid-acting profiles than regular human insulin. glulisine 17-26 insulin Homo sapiens 9-16 16151977-6 2005 Fractional glucose infusion rate (GIR)-area under curves (AUC) of the GIR curve and maximum GIR were greater for insulin glulisine and insulin lispro versus regular human insulin. glulisine 121-130 insulin Homo sapiens 113-120 16151977-7 2005 Total glucose disposal was slightly greater with insulin glulisine than with regular human insulin, and was comparable to insulin lispro, although it decreased with increasing insulin resistance (HOMA index) with all insulins. glulisine 57-66 insulin Homo sapiens 49-56 16151977-8 2005 Time to 20 % (early glucose disposal) and 80 % (bulk of activity) of total GIR-AUC were shorter for insulin glulisine and insulin lispro versus regular human insulin. glulisine 108-117 insulin Homo sapiens 100-107 16151977-9 2005 This was corroborated by more rapid and shorter residing pharmacokinetic profiles of insulin glulisine and insulin lispro versus regular human insulin, evidenced by shorter times to 20 % of total INS-AUC, INS-C (max) (INS-t (max)), and mean residence time. glulisine 93-102 insulin Homo sapiens 85-92 16151977-10 2005 Moreover, time to 20 % of total GIR-AUC demonstrated a less rapid-acting profile for insulin lispro versus insulin glulisine, which was consistent with the slightly less rapid pharmacokinetic profile of insulin lispro. glulisine 115-124 insulin Homo sapiens 107-114 16151977-10 2005 Moreover, time to 20 % of total GIR-AUC demonstrated a less rapid-acting profile for insulin lispro versus insulin glulisine, which was consistent with the slightly less rapid pharmacokinetic profile of insulin lispro. glulisine 115-124 insulin Homo sapiens 107-114 16151977-12 2005 CONCLUSIONS/INTERPRETATION: Insulin glulisine and insulin lispro demonstrated substantially more rapid time-action profiles than regular human insulin in obese non-diabetic subjects, which prevailed with insulin glulisine irrespective of BMI and subcutaneous fat thickness. glulisine 36-45 insulin Homo sapiens 28-35 16151977-12 2005 CONCLUSIONS/INTERPRETATION: Insulin glulisine and insulin lispro demonstrated substantially more rapid time-action profiles than regular human insulin in obese non-diabetic subjects, which prevailed with insulin glulisine irrespective of BMI and subcutaneous fat thickness. glulisine 212-221 insulin Homo sapiens 28-35 16151977-12 2005 CONCLUSIONS/INTERPRETATION: Insulin glulisine and insulin lispro demonstrated substantially more rapid time-action profiles than regular human insulin in obese non-diabetic subjects, which prevailed with insulin glulisine irrespective of BMI and subcutaneous fat thickness. glulisine 212-221 insulin Homo sapiens 50-57 16193096-0 2005 Insulin glulisine. glulisine 8-17 insulin Homo sapiens 0-7 16193096-3 2005 One of the newest members of this class of hypoglycemic agents is insulin glulisine, a rapid-acting insulin analog with a pharmacokinetic profile that more closely mimics the natural pattern of insulin secretion than regular human insulin. glulisine 74-83 insulin Homo sapiens 66-73 16193096-3 2005 One of the newest members of this class of hypoglycemic agents is insulin glulisine, a rapid-acting insulin analog with a pharmacokinetic profile that more closely mimics the natural pattern of insulin secretion than regular human insulin. glulisine 74-83 insulin Homo sapiens 100-107 16193096-3 2005 One of the newest members of this class of hypoglycemic agents is insulin glulisine, a rapid-acting insulin analog with a pharmacokinetic profile that more closely mimics the natural pattern of insulin secretion than regular human insulin. glulisine 74-83 insulin Homo sapiens 100-107 16193096-3 2005 One of the newest members of this class of hypoglycemic agents is insulin glulisine, a rapid-acting insulin analog with a pharmacokinetic profile that more closely mimics the natural pattern of insulin secretion than regular human insulin. glulisine 74-83 insulin Homo sapiens 100-107 16193096-4 2005 Subcutaneous administration of insulin glulisine has a faster subcutaneous absorption, a more rapid onset of activity, and a shorter duration of action than regular human insulin. glulisine 39-48 insulin Homo sapiens 31-38 16193096-4 2005 Subcutaneous administration of insulin glulisine has a faster subcutaneous absorption, a more rapid onset of activity, and a shorter duration of action than regular human insulin. glulisine 39-48 insulin Homo sapiens 171-178 16193096-5 2005 These properties of insulin glulisine allow it to be administered shortly before or soon after meals by subcutaneous injection or by continuous subcutaneous pump infusion. glulisine 28-37 insulin Homo sapiens 20-27 16193096-6 2005 Insulin glulisine effectively controls postprandial glucose excursions in both type 1 and type 2 diabetic patients without increasing the risk of hypoglycemia. glulisine 8-17 insulin Homo sapiens 0-7 16193096-7 2005 One unit of insulin glulisine has the same glucose-lowering effect as one unit of regular human insulin. glulisine 20-29 insulin Homo sapiens 12-19 16193096-8 2005 Insulin glulisine has a favorable safety profile, which is not significantly different from that of regular human insulin. glulisine 8-17 insulin Homo sapiens 0-7 16193096-9 2005 This review summarizes the current data on the clinical efficacy and safety of insulin glulisine in type 1 and type 2 diabetic patients. glulisine 87-96 insulin Homo sapiens 79-86 15926116-9 2005 At steady state (90 - 120 min), insulin glulisine and RHI had equivalent glucose utilization (GIR-AUC (SS), 209 [corrected] mg . glulisine 40-49 insulin Homo sapiens 32-39 15926116-19 2005 In conclusion, insulin glulisine and RHI show similar distribution and elimination profiles and equivalent glucodynamic efficacy on a molar, unit-per-unit basis. glulisine 23-32 insulin Homo sapiens 15-22 15934890-5 2005 These data highlight the flexibility in the dosing schedule with insulin glulisine. glulisine 73-82 insulin Homo sapiens 65-72 15934890-6 2005 Clinical trials have demonstrated that insulin glulisine elicits a greater reduction in glycosylated haemoglobin at end point than RHI, in both type 1 and 2 diabetes mellitus. glulisine 47-56 insulin Homo sapiens 39-46 15934890-7 2005 In addition, the safe administration of insulin glulisine by continuous subcutaneous insulin infusion has been demonstrated in patients with type 1 diabetes. glulisine 48-57 insulin Homo sapiens 40-47 15934890-7 2005 In addition, the safe administration of insulin glulisine by continuous subcutaneous insulin infusion has been demonstrated in patients with type 1 diabetes. glulisine 48-57 insulin Homo sapiens 85-92 15934890-8 2005 In conclusion, insulin glulisine is an effective, safe and well-tolerated rapid-acting insulin analogue. glulisine 23-32 insulin Homo sapiens 15-22 15934890-8 2005 In conclusion, insulin glulisine is an effective, safe and well-tolerated rapid-acting insulin analogue. glulisine 23-32 insulin Homo sapiens 87-94 15926116-0 2005 A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. glulisine 119-128 insulin Homo sapiens 111-118 15926116-0 2005 A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. glulisine 119-128 insulin Homo sapiens 111-118 15926116-1 2005 Insulin glulisine is a new rapid-acting insulin analog. glulisine 8-17 insulin Homo sapiens 0-7 15926116-1 2005 Insulin glulisine is a new rapid-acting insulin analog. glulisine 8-17 insulin Homo sapiens 40-47 15926116-2 2005 The aim of this study was to assess the glucodynamic efficacy of insulin glulisine compared with regular human insulin (RHI) using a manual euglycemic clamp technique. glulisine 73-82 insulin Homo sapiens 65-72 15934890-0 2005 Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. glulisine 8-17 insulin Homo sapiens 38-45 15934890-1 2005 Insulin glulisine (Apidra, Sanofi-Aventis), a new and recently approved rapid-acting insulin analogue, mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin, but has a rapid onset, peak effect at 1h, and a shorter duration of action (approximately 4 h). glulisine 8-17 insulin Homo sapiens 0-7 15934890-1 2005 Insulin glulisine (Apidra, Sanofi-Aventis), a new and recently approved rapid-acting insulin analogue, mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin, but has a rapid onset, peak effect at 1h, and a shorter duration of action (approximately 4 h). glulisine 8-17 insulin Homo sapiens 85-92 15934890-1 2005 Insulin glulisine (Apidra, Sanofi-Aventis), a new and recently approved rapid-acting insulin analogue, mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin, but has a rapid onset, peak effect at 1h, and a shorter duration of action (approximately 4 h). glulisine 8-17 insulin Homo sapiens 182-189 15934890-3 2005 Formal clinical evaluations show that insulin glulisine can be administered safely and effectively pre- and postmeal. glulisine 46-55 insulin Homo sapiens 38-45 15934890-4 2005 When injected immediately premeal, insulin glulisine provides superior postprandial blood glucose control compared with regular human insulin (RHI) injected 30 min premeal. glulisine 43-52 insulin Homo sapiens 35-42 15677493-0 2005 Insulin glulisine: insulin receptor signaling characteristics in vivo. glulisine 8-17 insulin Homo sapiens 0-7 15677493-6 2005 The extent and time course of insulin receptor phosphorylation and activation of downstream signaling elements after insulin glulisine treatment was similar to that of human regular insulin in vivo. glulisine 125-134 insulin Homo sapiens 30-37 15677493-0 2005 Insulin glulisine: insulin receptor signaling characteristics in vivo. glulisine 8-17 insulin Homo sapiens 19-26 15677493-6 2005 The extent and time course of insulin receptor phosphorylation and activation of downstream signaling elements after insulin glulisine treatment was similar to that of human regular insulin in vivo. glulisine 125-134 insulin Homo sapiens 117-124 15677493-8 2005 Therefore, insulin glulisine may be a useful tool for diabetes treatment. glulisine 19-28 insulin Homo sapiens 11-18 15677493-4 2005 In this study, we determined in vivo the insulin receptor signaling characteristics activated by insulin glulisine (Lys(B3), Glu(B29)) at the level of insulin receptor phosphorylation, insulin receptor substrate phosphorylation, and downstream signaling elements such as phosphatidylinositol (PI) 3-kinase, AKT, and mitogen-activated protein kinase. glulisine 105-114 insulin Homo sapiens 41-48 15677493-4 2005 In this study, we determined in vivo the insulin receptor signaling characteristics activated by insulin glulisine (Lys(B3), Glu(B29)) at the level of insulin receptor phosphorylation, insulin receptor substrate phosphorylation, and downstream signaling elements such as phosphatidylinositol (PI) 3-kinase, AKT, and mitogen-activated protein kinase. glulisine 105-114 insulin Homo sapiens 97-104 15677493-4 2005 In this study, we determined in vivo the insulin receptor signaling characteristics activated by insulin glulisine (Lys(B3), Glu(B29)) at the level of insulin receptor phosphorylation, insulin receptor substrate phosphorylation, and downstream signaling elements such as phosphatidylinositol (PI) 3-kinase, AKT, and mitogen-activated protein kinase. glulisine 105-114 insulin Homo sapiens 97-104 15677493-4 2005 In this study, we determined in vivo the insulin receptor signaling characteristics activated by insulin glulisine (Lys(B3), Glu(B29)) at the level of insulin receptor phosphorylation, insulin receptor substrate phosphorylation, and downstream signaling elements such as phosphatidylinositol (PI) 3-kinase, AKT, and mitogen-activated protein kinase. glulisine 105-114 insulin Homo sapiens 97-104 15451901-0 2004 Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. glulisine 8-17 insulin Homo sapiens 0-7 16033730-0 2005 Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. glulisine 67-76 insulin Homo sapiens 59-66 15451901-1 2004 OBJECTIVE: Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. glulisine 19-28 insulin Homo sapiens 11-18 15451901-1 2004 OBJECTIVE: Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. glulisine 19-28 insulin Homo sapiens 56-63 15451901-1 2004 OBJECTIVE: Insulin glulisine is a novel analog of human insulin designed for use as a rapid-acting insulin. glulisine 19-28 insulin Homo sapiens 99-106 15451901-9 2004 CONCLUSIONS: Twice-daily glulisine associated with NPH can provide small improvements in glycemic control compared with RHI in patients with type 2 diabetes who are already relatively well controlled on insulin alone or insulin plus OADs. glulisine 25-34 insulin Homo sapiens 203-210 33776458-1 2021 Aim: In the present analysis, we characterised the efficacy and safety of adding a single daily injection of insulin glulisine to optimised basal-supported oral therapy (BOT) in patients with a high BeAM value, defined as a more than 50 mg/dl difference between bedtime and pre-breakfast blood glucose. glulisine 117-126 insulin Homo sapiens 109-116 35591905-10 2022 Conclusion: The insulin glulisine intensification regimen showed glycemic target achievement and can be considered a therapeutic tool in the management of T2DM patients. glulisine 24-33 insulin Homo sapiens 16-23 29632561-4 2015 Here, all post-marketing and clinical trials safety data with insulin glulisine in pregnancy available to Sanofi up to June 2014 are summarised together with the findings of a comprehensive literature search. glulisine 70-79 insulin Homo sapiens 62-69 34551215-7 2022 However, the time below range level 1 was lower in the iGlarLixi + insulin glulisine group (p=0.047). glulisine 75-84 insulin Homo sapiens 67-74 34551215-8 2022 The changes in glycemic variability, therapeutic indices, and body mass index were not significantly different between the groups, although the titration period was significantly shorter in the iGlarLixi + insulin glulisine group (p=0.033). glulisine 214-223 insulin Homo sapiens 206-213 34551215-9 2022 CONCLUSIONS: iGlarLixi + insulin glulisine combination therapy is safe and equally efficacious as multiple daily injection therapy for glycemic control, while avoiding hypoglycemia risk and reducing the number of injections are required. glulisine 33-42 insulin Homo sapiens 25-32 29632561-0 2015 Insulin Glulisine in Pregnancy - Experience from Clinical Trials and Post-marketing Surveillance. glulisine 8-17 insulin Homo sapiens 0-7 29632561-3 2015 Insulin glulisine (Apidra , Sanofi) is a rapid-acting insulin analogue indicated for the treatment of adults, adolescents and children 6 years or older with diabetes mellitus where treatment with insulin is required. glulisine 8-17 insulin Homo sapiens 0-7 29632561-3 2015 Insulin glulisine (Apidra , Sanofi) is a rapid-acting insulin analogue indicated for the treatment of adults, adolescents and children 6 years or older with diabetes mellitus where treatment with insulin is required. glulisine 8-17 insulin Homo sapiens 54-61 29632561-3 2015 Insulin glulisine (Apidra , Sanofi) is a rapid-acting insulin analogue indicated for the treatment of adults, adolescents and children 6 years or older with diabetes mellitus where treatment with insulin is required. glulisine 8-17 insulin Homo sapiens 196-203 33719017-2 2021 Investigations have suggested rapid-acting insulins such as glulisine may result in superior cognitive benefits compared with regular insulin. glulisine 60-69 insulin Homo sapiens 43-50 32861229-10 2022 In type 1 diabetes, only insulin glulisine, detemir, and lispro were non-affordable in monotherapy. glulisine 33-42 insulin Homo sapiens 25-32 33592769-5 2021 This study describes the first validated quantitative method for analysis human insulin and its six analogues (lispro, aspart, glulisine, glargine, detemir and degludec) in plasma and post-mortem sera. glulisine 127-136 insulin Homo sapiens 80-87 32386349-3 2020 In the present report, the development and validation of a sensitive analytical strategy is described for the urinary detection of three rapid-acting insulin analogues (Lispro, Aspart, Glulisine). glulisine 185-194 insulin Homo sapiens 150-157 32738019-12 2020 CONCLUSIONS: Although the present pilot study is based on a small sample, the data give first hint that the use of the zinc-free insulin glulisine may be beneficial in people with diabetes, pump and lipoatrophy. glulisine 137-146 insulin Homo sapiens 129-136 33544355-0 2021 Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naive Patients with Type 2 Diabetes: The Observational IGLU-SIT Study. glulisine 36-45 insulin Homo sapiens 28-35 33544355-0 2021 Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naive Patients with Type 2 Diabetes: The Observational IGLU-SIT Study. glulisine 36-45 insulin Homo sapiens 85-92 33544355-1 2021 INTRODUCTION: The IGLU-SIT study documented the effectiveness of initiating supplementary prandial insulin treatment (SIT) with insulin glulisine after failure of oral antidiabetic drugs alone in patients with type 2 diabetes (T2DM) in a real-world setting in Germany. glulisine 136-145 insulin Homo sapiens 99-106 33544355-1 2021 INTRODUCTION: The IGLU-SIT study documented the effectiveness of initiating supplementary prandial insulin treatment (SIT) with insulin glulisine after failure of oral antidiabetic drugs alone in patients with type 2 diabetes (T2DM) in a real-world setting in Germany. glulisine 136-145 insulin Homo sapiens 128-135 33544355-12 2021 CONCLUSION: Initiating SIT with insulin glulisine is an appropriate treatment option in patients whose T2DM is insufficiently controlled. glulisine 40-49 insulin Homo sapiens 32-39 33544356-0 2021 Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study. glulisine 71-80 insulin Homo sapiens 51-58 33544356-1 2021 INTRODUCTION: The IGLU-S study assessed the effectiveness of insulin glulisine after switching from human insulin/other rapid-acting insulin analogues in patients with type 1 diabetes (T1DM) and type 2 diabetes (T2DM) in a real-world setting in Germany. glulisine 69-78 insulin Homo sapiens 61-68 33544356-7 2021 After insulin glulisine introduction, the proportion of patients achieving their individual HbA1c increased to 43.6% (T1DM) and 39.6% (T2DM) of patients at 12 months. glulisine 14-23 insulin Homo sapiens 6-13 33544356-12 2021 CONCLUSION: Switching prandial insulin to insulin glulisine resulted in improved effectiveness with 43.6% of T1DM and 39.6% of T2DM patients reaching their individual pre-defined HbA1c target within 1 year. glulisine 50-59 insulin Homo sapiens 42-49 33462295-0 2021 Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques. glulisine 20-29 insulin Homo sapiens 12-19 33462295-1 2021 This study concerns glulisine, a rapid-acting insulin analogue that plays a fundamental role in diabetes management. glulisine 20-29 insulin Homo sapiens 46-53 33251697-2 2021 METHODS: Participants were randomly assigned to groups for therapy with insulin glulisine (IGlu) or insulin glargine (IGla). glulisine 80-89 insulin Homo sapiens 72-79 32478645-0 2020 Long-term stability of insulin glulisine loaded nanoparticles formulated using an amphiphilic cyclodextrin and designed for intestinal delivery. glulisine 31-40 insulin Homo sapiens 23-30 32478645-3 2020 The aim of this work was to evaluate the stability of amphiphilic cyclodextrin-based nanoparticles (NPs) containing insulin glulisine. glulisine 124-133 insulin Homo sapiens 116-123 32478645-8 2020 Following intra-intestinal administration of the freeze-dried formulation, while no lowering of blood glucose was seen, insulin glulisine was detected in both portal and systemic blood indicating that potential exists for further development of the formulation to simultaneously achieve prolonged stability and therapeutic efficacy. glulisine 128-137 insulin Homo sapiens 120-127 31376619-0 2019 The quaternary structure of insulin glargine and glulisine under formulation conditions. glulisine 49-58 insulin Homo sapiens 28-35 31984772-12 2020 For the last two months of her life, she gave permission for degludec + glulisine insulin intensive treatment. glulisine 72-81 insulin Homo sapiens 82-89 31376619-2 2019 Our results revealed that insulin glulisine in Apidra is predominantly hexameric in solution with significant fractions of dodecamers and monomers. glulisine 34-43 insulin Homo sapiens 26-33 31096094-2 2019 Herein, a qualitative proteomic method is presented for the identification of recombinant human insulin and all marketed biosynthetic analogues -insulin lispro, aspart, glulisine, glargine, detemir and degludec- via tryptic digestion and identification of proteotypic peptides for each insulin. glulisine 169-178 insulin Homo sapiens 96-103 30063113-8 2018 In this study we evaluated the complexation of insulin glulisine, an insulin analogue administered subcutaneously or intravenously in clinical practice, with a well-known CPP modified with the MCFA lauric acid. glulisine 55-64 insulin Homo sapiens 47-54 30556900-1 2018 BACKGROUND: The use of short-acting insulin analogues (insulin lispro, insulin aspart, insulin glulisine) for adult, non-pregnant people with type 2 diabetes is still controversial, as reflected in many scientific debates. glulisine 95-104 insulin Homo sapiens 36-43 30545262-0 2018 [Effectiveness of one-year insulin glargine and insulin glulisine basal-bolus treatment in people with type 2 diabetes. glulisine 56-65 insulin Homo sapiens 27-55 30545262-4 2018 AIM: The aims of the study were to investigate the effectiveness of insulin glargine + insulin glulisine basal-bolus regimen from the payer"s perspective and to investigate the ability to maintain the achieved glycaemic control in previously uncontrolled T2DM patients (HbA1c >9.0%). glulisine 95-104 insulin Homo sapiens 68-75 30545262-4 2018 AIM: The aims of the study were to investigate the effectiveness of insulin glargine + insulin glulisine basal-bolus regimen from the payer"s perspective and to investigate the ability to maintain the achieved glycaemic control in previously uncontrolled T2DM patients (HbA1c >9.0%). glulisine 95-104 insulin Homo sapiens 87-94 30545262-12 2018 CONCLUSIONS: More than half of the patients with T2DM who were newly switched to insulin glargine + glulisine basal-bolus treatment could achieve the reimbursement rule criteria requiring for prescription of the analogue insulins with no co-payment beyond 1 year of treatment in Hungary. glulisine 100-109 insulin Homo sapiens 81-88 30063113-8 2018 In this study we evaluated the complexation of insulin glulisine, an insulin analogue administered subcutaneously or intravenously in clinical practice, with a well-known CPP modified with the MCFA lauric acid. glulisine 55-64 insulin Homo sapiens 69-76